Arithmos Capital

Arithmos does not fit a standard fund-commitment or direct-deal private equity model. The firm channels capital into service delivery for life sciences companies, building and running the software and compliance workflows that underpin drug development, quality management, and pharmacovigilance. Its disclosed partner network — Veeva, Oracle, Agatha, SAS, and Deep — forms the backbone of its deployment.

Arithmos does not publicly identify any named principals, investment committee members, or managing partners. Its public-facing materials highlight project managers, business analysts, and practice leads, but no individual with formal investment authority is disclosed.

No. The firm is categorized as an asset manager in available records, but its observable activities — IT consulting, business-process outsourcing execution, and system-integration services for life sciences — align it more closely with a specialist services company than a blind-pool capital allocator.

The firm structures its work into Quality & Compliance (QMS design, GxP auditing, regulatory inspection preparation), Pharmacovigilance (case and document management, literature screening, safety database integration), Regulatory Affairs (drug development, product lifecycle management), and Clinical Development (trial oversight, data maximization, document management).

Arithmos does not publicly disclose its fee structure. The company offers project-based assessment, end-to-end system delivery, and staff augmentation, but whether it earns management fees, carries interest, or pure consulting fees cannot be verified from available sources.